Development and Optimization of a Novel Synthetic Route for 2,4-Diamine-quinazoline Containing Ziresovir: A Drug Candidate for the Treatment of Respiratory Syncytial Virus (RSV) Infection.

Changtai You, Dingding Wang, Chuang He, Muhammad Kashif Zaman, Haibin Zhang, Tao Wang, Zifeng Yang, Lili Hu, Yingjun Li

Abstract read

In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Changtai YouSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Dingding WangSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Chuang HeState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510180, China.

Muhammad Kashif ZamanState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510180, China.

Haibin ZhangState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510180, China.

Tao WangState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510180, China.

Zifeng YangState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510180, China.

Lili HuSchool of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Yingjun LiState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510180, China.ORCID https://orcid.org/0000-0002-8376-1811

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ziresovir (AK0529) is a potent fusion (F) protein inhibitor featuring a quinazoline-2,4-diamine core and is currently a Phase III clinical drug candidate for the treatment of respiratory syncytial virus (RSV) infectious diseases. The existing synthetic routes to Ziresovir involve two consecutive nucleophilic substitutions on 2,4-dichloro-6-methylquinazoline with amines, which often result in undesired side products and require harsh conditions for the second chlorine substitution. In this study, we report the development and optimization of a streamlined, three-step synthesis of Ziresovir. The process begins with a copper-catalyzed ring closure reaction between 2-bromobenzoic acid and guanidine to form substituted quinazoline scaffolds. Subsequent chlorination with POCl

Identifiers

PMID40893310

DOI10.1021/acsomega.5c06080

PMCPMC12391931

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.